Download presentation
Presentation is loading. Please wait.
Published byАнтоније Јовичић Modified over 6 years ago
1
Inferior Vena Cava Filter Usage, Complications, and Retrieval Rate in Cancer Patients
Farhad Abtahian, MD, PhD, Beau M. Hawkins, MD, David P. Ryan, MD, Philip Cefalo, MD, Nicola J. Nasser, MD, PhD, Cheryl MacKay, RN, Michael R. Jaff, DO, Ido Weinberg, MD The American Journal of Medicine Volume 127, Issue 11, Pages (November 2014) DOI: /j.amjmed Copyright © 2014 Elsevier Inc. Terms and Conditions
2
Figure (A) Time to death, deep vein thrombosis, pulmonary embolism, or inferior vein cava thrombosis (overall P < .001; no malignancy vs carcinoma P < .001; no malignancy vs sarcoma, P = .022; carcinoma vs sarcoma P = .27). (B) Time to deep vein thrombosis, pulmonary embolism, or inferior vena cava thrombosis (overall P-value = .970; no malignancy vs carcinoma P-value = .80, no malignancy vs sarcoma, P-value = .76, carcinoma vs sarcoma P-value = .64). (C) Time to death, deep vein thrombosis, pulmonary embolism, or inferior vein cava thrombosis (overall P < .001; no malignancy vs localized P = .29; no malignancy vs metastatic, P < .001; localized vs metastatic P < .001). (D) Time to deep vein thrombosis, pulmonary embolism or inferior vena cava thrombosis (overall P-value = 0.396; no malignancy vs localized P = .45; no malignancy vs metastatic P = .35; localized vs metastatic P = .169). IVCF = inferior vena cava filter. The American Journal of Medicine , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.